Pharmaceutical Companies Stress Innovative Research For Success

Date : December 12, 1994 Sidebar: PHARMACEUTICAL INDUSTRY JOB STATISTICS As 1995 approaches, changing economic forces in the pharmaceutical industry are presenting its scientists with tough challenges, both professional and scientific, according to researchers, company officials, and other observers. Financial setbacks and shifting business dynamics, such as mergers and takeovers, have caused companies to drastically downsize thei

Written byNeeraja Sankaran
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Date : December 12, 1994

Sidebar: PHARMACEUTICAL INDUSTRY JOB STATISTICS

As 1995 approaches, changing economic forces in the pharmaceutical industry are presenting its scientists with tough challenges, both professional and scientific, according to researchers, company officials, and other observers.

Financial setbacks and shifting business dynamics, such as mergers and takeovers, have caused companies to drastically downsize their work force in recent years, they say, with more cuts anticipated. "There were some 40,000 layoffs through the entire industry in the last two to 21/2 years, and the industry will become leaner still in the years to come," predicts Robert Ruffolo, Jr., vice president and director of pharmacological sciences departments at Philadelphia-based SmithKline Beecham Laboratories.

For scientists surviving the carnage, observers maintain, the pressure is on to focus on novel ideas and to increase efficiency in discovering and producing new drugs. "Innovation has to be part of everybody's job description," stresses Mary ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies